Heterozygous germ-line mutations in the NBN gene predispose to medulloblastoma in pediatric patients

Acta Neuropathologica

Volumn 119, Issue 3, 2010, Pages 325-334

  Ciara, Elzbieta ^a   Piekutowska Abramczuk, Dorota ^a   Popowska, Ewa ^a   Grajkowska, Wieslawa ^a   Barszcz, Slawomir ^a   Perek, Danuta ^a   Dembowska Bagińska, Bozenna ^a   Perek Polnik, Marta ^a   Kowalewska, Ewa ^a   Czajńska, Aneta ^a   Syczewska, Malgorzata ^a   Czornak, Kamila ^a   Krajewska Walasek, Malgorzata ^a   Roszkowski, Marcin ^a   Chrzanowska, Krystyna H ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Cancer risk; Germ line mutations; Medulloblastoma; NBN gene

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; NIBRIN; VINCRISTINE;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CHILD; EXON; FEMALE; GENE FREQUENCY; GENE LOCATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIABILITY; GERM LINE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADOLESCENT; CELL CYCLE PROTEINS; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; DNA, NEOPLASM; EXONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; MOLECULAR SEQUENCE DATA; NIJMEGEN BREAKAGE SYNDROME; NUCLEAR PROTEINS; POLAND; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 77953020607     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-009-0608-y     Document Type: Article

References (56)

1. Abner CW, McKinnon PJ (2004) The DNA double-strand break response in the nervous system. DNA Repair 3:1141-1147.
2. Aldosari N, Bigner SH, Burger PC et al (2002) MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 126(5):540-544.
3. Badiali M, Iolascon A, Loda M et al (1993) p53 gene mutations in medulloblastoma. Immunohistochemistry, gel shift analysis, and sequencing. Diagn Mol Pathol 2(1):23-28.
4. Bakhshi S, Cerosaletti KM, Concannon P et al (2003) Medulloblastoma with adverse reaction to radiation therapy in Nijmegen breakage syndrome. J Pediatr Hematol Oncol 25(3):248-251.
5. Baylin S (2001) DNA methylation and epigenetic mechanisms of carcinogenesis. Dev Biol (Basel) 106:85-87 (discussion 143-160).
6. Becker E, Meyer V, Madaoui H, Guerois R (2006) Detection of a tandem BRCT in Nbs1 and Xrs2 with functional implications in the DNA damage response. Bioinformatics 22(11):1289-1292.
7. Bigner SH, Mark J, Friedman HS, Biegel JA, Bigner DD (1988) Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet 30:91-101. (Pubitemid 18033792)
8. Bogdanova N, Feshchenko S, Schürmann P et al (2008) Nijmegen breakage syndrome mutations and risk of breast cancer. Int J Cancer 122:802-806.
9. Bürger S, Schindler D, Fehn M et al (2006) Radiation-induced DNA damage and repair in peripheral blood mononuclear cells from Nijmegen breakage syndrome patients and carriers assessed by the Comet assay. Environ Mol Mutagen 47(4):260-270.
10. Carney JP, Maser RS, Olivares H et al (1998) The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 93:477-486.
11. Chang CH, Housepian EM, Herbert C (1969) An operative staging system and a megavoltage radiotherapic technique for cerebellar medulloblastomas. Radiology 93:1351-1359.
12. Chrzanowska KH, Piekutowska-Abramczuk D, Popowska E et al (2006) Carrier frequency of mutation 657del5 in the NBS1 gene in a population of Polish pediatric patients with sporadic lymphoid malignancies. Int J Cancer 118:1269-1274.
13. Cybulski C, Górski B, Debniak T et al (2004) NBS1 is a prostate cancer susceptibility gene. Cancer Res 64:1215-1219. (Pubitemid 38235583)
14. Dallas PB, Terry PA, Kees UR (2005) Genomic deletions in cell lines derived from primitive neuroectodermal tumors of the central nervous system. Cancer Genet Cytogenet 159(2):105-113.
15. Distel L, Neubauer S, Varon R, Holter W, Grabenbauer G (2003) Fatal toxicity following radio- and chemotherapy of medulloblastoma in a child with unrecognized Nijmegen breakage syndrome. Med Pediatr Oncol 41(1):44-48.
16. Dumon-Jones V, Frappart PO, Tong WM et al (2003) Nbn heterozygosity renders mice susceptible to tumor formation and ionizing radiation-induced tumorigenesis. Cancer Res 63(21):7263-7269.
17. Frappart PO, Lee Y, Lamont J, McKinnon PJ (2007) BRCA2 is required for neurogenesis and suppression of medulloblastoma. EMBO J 26:2732-2742.
18. Górski B, Debniak T, Masojć B et al (2003) Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer 106:379-381.
19. Hama S, Matsuura S, Tauchi H et al (2000) Absence of mutations in the NBS1 gene in B-cell malignant lymphoma patients. Anticancer Res 20:1897-1900.
20. Hebbring SJ, Fredriksson H, White KA et al (2006) Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 15:935-938.
21. Heikkinen K, Rapakko K, Karppinen SM et al (2006) NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 27(8):1593-1599.
22. Hematulin A, Sagan D, Eckardt-Schupp F, Moertl S (2008) NBS1 is required for IGF-1 induced cellular proliferation through the Ras/Raf/MEK/ERK cascade. Cell Signal 20(12):2276-2285.
23. Hope AJ, Mansur DB, Tu PH, Simpson JR (2006) Metachronous secondary atypical meningioma and anaplastic astrocytoma after postoperative craniospinal irradiation for medulloblastoma. Childs Nerv Syst 22(9):1201-1207.
24. Huang H, Mahler-Araujo BM, Sankila A et al (2000) APC mutations in sporadic medulloblastomas. Am J Pathol 156(2):433- 437.
25. Huang J, Grotzer MA, Watanabe T et al (2008) Mutations in the Nijmegen breakage syndrome gene in medulloblastomas. Clin Cancer Res 14:4053-4058.
26. Iijima K, Muranaka C, Kobayashi J et al (2008) NBS1 regulates a novel apoptotic pathway through Bax activation. DNA Repair (Amst) 7(10):1705-1716.
27. Jones PA, Takai D (2001) The role of DNA methylation in mammalian epigenetics. Science 10:1068-1070.
28. Kanka C, Brozek I, Skalska B, Siemiatkowska A, Limon J (2007) Germline NBS1 mutations in families with aggregation of Breast and/or ovarian cancer from north-east Poland. Anticancer Res 27:3015-3018.
29. Kobayashi J, Antoccia A, Tauchi H, Matsuura S, Komatsu K (2004) NBS1 and its functional role in the DNA damage response. DNA Repair 3:855-861.
30. Lindsey JC, Lusher ME, Anderton JA, Gilbertson RJ, Ellison DW, Clifford SC (2007) Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma. Br J Cancer 97(2):267-274.
31. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97-109.
32. Marino S (2005) Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 11:17-22.
33. McNeil DE, Coté TR, Clegg L, Rorke LB (2002) Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance epidemiology and end results. Med Pediatr Oncol 39:190-194.
34. Mosor M, Ziółkowska I, Pernak-Schwarz M, Januszkiewicz-Lewandowska D, Nowak J (2006) Association of the heterozygous germline I171V mutation of the NBS1 gene with childhood acute lymphoblastic leukemia. Leukemia 20:1454-1456.
35. Neglia JP, Friedman DL, Yasui Y et al (2001) Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 93(8):618-629. (Pubitemid 32409629)
36. Neubauer S, Arutyunyan R, Stumm M et al (2002) Radiosensitivity of ataxia telangiectasia and Nijmegen breakage syndrome homozygotes and heterozygotes as determined by three-color FISH chromosome painting. Radiat Res 157(3):312-321.
37. Nowak J, Mosor M, Ziółkowska I et al (2008) Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumours. Eur J Cancer 44:627-630.
38. Piekutowska-Abramczuk D, Ciara E, Popowska E, et al. (2009) The frequency of NBN molecular variants in pediatric astrocytic tumors. J Neurooncol 22 (Epub ahead). doi:10.1007/s11060- 009-9958-5.
39. Raffel C, Jenkins RB, Frederick L et al (1997) Sporadic medulloblastomas contain PTCH mutations. Cancer Res 57(5):842-845.
40. Rischewski J, Bismarck P, Kabisch H, Janka-Schaub G, Obser T, Schneppenheim R (2000) The common deletion 657del5 in the Nibrin gene is not a major risk factor for B or T cell non-Hodgkin lymphoma in a pediatric population. Leukemia 14:1528-1529.
41. Santarosa M, Ashworth A (2004) Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta 1654(2):105-122.
42. Seemanová E, Jarolim P, Seeman P et al (2007) Cancer risk of heterozygotes with the NBN founder mutation. J Natl Cancer Inst 99(24):1875-1880.
43. Shimada H, Shimizu K, Mimaki S et al (2004) First case of aplastic anemia in a Japanese child with a homozygous missense mutation in the NBS1 gene (I171V) associated with genomic instability. Hum Genet 115(5):372-376.
44. Sokolenko AP, Rozanov ME, Mitiushkina NV et al (2007) Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam Cancer 6:281-286.
45. Steffen J, Nowakowska D, Niwińska A et al (2006) Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer 119:472-475.
46. Steffen J, Varon R, Mosor M, Maneva G et al (2004) Increased cancer risk of heterozygotes with NBS1 germline mutations in Poland. Int J Cancer 111:67-71.
47. Tanzarella C, Antoccia A, Spadoni E et al (2003) Chromosome instability and nibrin protein variants in NBS heterozygotes. Eur J Hum Genet 11(4):297-303.
48. Taylor MD, Mainprize TG, Rutka JT, Becker L, Bayani J, Drake JM (2001) Medulloblastoma in a child with Rubenstein-Taybi Syndrome: case report and review of the literature. Pediatr Neurosurg 35:235-238. (Pubitemid 34008796)
49. Varon R, Reis A, Henze G, von Einsiedel HG, Sperling K, Seeger K (2001) Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res 61:3570-3572.
50. Varon R, Seemanova E, Chrzanowska K et al (2000) Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet 8:900-902.
51. Varon R, Vissinga C, Platzer M et al (1998) Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93:467-476.
52. Watanabe T, Nobusawa S, Lu S, Huang J, Mittelbronn M, Ohgaki H (2009) Mutational inactivation of the Nijmegen Breakage Syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations. J Neuropathol Exp Neurol 68(2):210- 215.
53. Wegner RD, German JJ, Chrzanowska KH, Digweed M, Stumm M (2007) Chromosomal instability syndromes other than ataxiatelangiectasia. In: Ochs HD, Smith CIE, Puck JM (eds) Primary immunodeficiency diseases. A molecular and genetic approach. Oxford University Press, Oxford, pp 427-453.
54. Ziólkowska I, Mosor M, Nowak J (2006) Regional distribution of heterozygous 657del5 mutation carriers of the NBS1 gene in Wielkopolska province (Poland). Appl Genet 47:269-272.
55. Ziólkowska I, Mosor M, Wierzbicka M, Rydzanicz M, Pernak-Schwarz M, Nowak J (2007) Increased risk of larynx cancer in heterozygous carriers of the I171 V mutation of the NBS1 gene. Cancer Sci 98:1701-1705.
56. Zurawel RH, Chiappa SA, Allen C, Raffel C (1998) Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 58(5):896-899.